Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.

Wong WW, Jackson RK, Liew LP, Dickson BD, Cheng GJ, Lipert B, Gu Y, Hunter FW, Wilson WR, Hay MP.

Biochem Pharmacol. 2019 Nov;169:113641. doi: 10.1016/j.bcp.2019.113641. Epub 2019 Sep 18.

PMID:
31541630
2.

Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.

Lee TW, Wong WW, Dickson BD, Lipert B, Cheng GJ, Hunter FW, Hay MP, Wilson WR.

Int J Radiat Biol. 2019 Sep 17:1-16. doi: 10.1080/09553002.2019.1664787. [Epub ahead of print]

PMID:
31490091
3.

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.

Hay MP, Shin HN, Wong WW, Sahimi WW, Vaz ATD, Yadav P, Anderson RF, Hicks KO, Wilson WR.

Molecules. 2019 Jul 10;24(14). pii: E2524. doi: 10.3390/molecules24142524.

4.

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors.

Dickson BD, Wong WW, Wilson WR, Hay MP.

Molecules. 2019 Apr 19;24(8). pii: E1559. doi: 10.3390/molecules24081559.

5.

Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.

Jackson RK, Liew LP, Hay MP.

Clin Oncol (R Coll Radiol). 2019 May;31(5):290-302. doi: 10.1016/j.clon.2019.02.004. Epub 2019 Mar 8.

PMID:
30853148
6.

Targeting growth hormone function: strategies and therapeutic applications.

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK.

Signal Transduct Target Ther. 2019 Feb 8;4:3. doi: 10.1038/s41392-019-0036-y. eCollection 2019. Review.

7.

Hypoxia-Activated Prodrugs of PERK Inhibitors.

Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay MP.

Chem Asian J. 2019 Apr 15;14(8):1238-1248. doi: 10.1002/asia.201801826. Epub 2019 Jan 29.

PMID:
30615821
8.

Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Chernikova SB, Nguyen RB, Truong JT, Mello SS, Stafford JH, Hay MP, Olson A, Solow-Cordero DE, Wood DJ, Henry S, von Eyben R, Deng L, Gephart MH, Aroumougame A, Wiese C, Game JC, Győrffy B, Brown JM.

J Clin Invest. 2018 Dec 3;128(12):5307-5321. doi: 10.1172/JCI87191. Epub 2018 Oct 29.

9.

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.

Biochem Pharmacol. 2018 Oct;156:265-280. doi: 10.1016/j.bcp.2018.08.027. Epub 2018 Aug 19.

PMID:
30134191
10.

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.

Bonnet M, Hong CR, Wong WW, Liew LP, Shome A, Wang J, Gu Y, Stevenson RJ, Qi W, Anderson RF, Pruijn FB, Wilson WR, Jamieson SMF, Hicks KO, Hay MP.

J Med Chem. 2018 Feb 8;61(3):1241-1254. doi: 10.1021/acs.jmedchem.7b01678. Epub 2018 Jan 11.

PMID:
29253343
11.

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.

Gu Y, Chang TT, Wang J, Jaiswal JK, Edwards D, Downes NJ, Liyanage HDS, Lynch CRH, Pruijn FB, Hickey AJR, Hay MP, Wilson WR, Hicks KO.

Front Pharmacol. 2017 Aug 11;8:531. doi: 10.3389/fphar.2017.00531. eCollection 2017.

12.

Chemical Space Mimicry for Drug Discovery.

Yuan W, Jiang D, Nambiar DK, Liew LP, Hay MP, Bloomstein J, Lu P, Turner B, Le QT, Tibshirani R, Khatri P, Moloney MG, Koong AC.

J Chem Inf Model. 2017 Apr 24;57(4):875-882. doi: 10.1021/acs.jcim.6b00754. Epub 2017 Apr 3.

13.

Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides.

Anderson RF, Yadav P, Shinde SS, Hong CR, Pullen SM, Reynisson J, Wilson WR, Hay MP.

Chem Res Toxicol. 2016 Aug 15;29(8):1310-24. doi: 10.1021/acs.chemrestox.6b00133. Epub 2016 Jul 29.

PMID:
27380897
14.

Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.

Hong CR, Wang J, Hicks KO, Hay MP.

Adv Exp Med Biol. 2016;899:269-90. doi: 10.1007/978-3-319-26666-4_16.

PMID:
27325273
15.

Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.

Jiang D, Tam AB, Alagappan M, Hay MP, Gupta A, Kozak MM, Solow-Cordero DE, Lum PY, Denko NC, Giaccia AJ, Le QT, Niwa M, Koong AC.

Mol Cancer Ther. 2016 Sep;15(9):2055-65. doi: 10.1158/1535-7163.MCT-15-1023. Epub 2016 Jun 15.

16.

Fragmentation of the quinoxaline N-oxide bond to the ˙OH radical upon one-electron bioreduction.

Yadav P, Marshall AJ, Reynisson J, Denny WA, Hay MP, Anderson RF.

Chem Commun (Camb). 2014 Nov 18;50(89):13729-31. doi: 10.1039/c4cc05657d.

PMID:
25248989
17.

Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.

Gu Y, Jaiswal JK, Wang J, Hicks KO, Hay MP, Wilson WR.

J Pharm Sci. 2014 Nov;103(11):3464-3472. doi: 10.1002/jps.24099. Epub 2014 Sep 11.

PMID:
25212501
18.

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

Anderson RF, Yadav P, Patel D, Reynisson J, Tipparaju SR, Guise CP, Patterson AV, Denny WA, Maroz A, Shinde SS, Hay MP.

Org Biomol Chem. 2014 Jun 7;12(21):3386-92. doi: 10.1039/c4ob00236a. Epub 2014 Apr 16.

PMID:
24737463
19.

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.

Bonnet M, Hong CR, Gu Y, Anderson RF, Wilson WR, Pruijn FB, Wang J, Hicks KO, Hay MP.

Bioorg Med Chem. 2014 Apr 1;22(7):2123-32. doi: 10.1016/j.bmc.2014.02.039. Epub 2014 Mar 3.

PMID:
24650701
20.

Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Bonnet M, Flanagan JU, Chan DA, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2014 Jan 15;22(2):711-20. doi: 10.1016/j.bmc.2013.12.028. Epub 2013 Dec 20.

21.

Hypoxia-directed drug strategies to target the tumor microenvironment.

Hay MP, Hicks KO, Wang J.

Adv Exp Med Biol. 2014;772:111-45. doi: 10.1007/978-1-4614-5915-6_6. Review.

PMID:
24272357
22.

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.

Green LK, Syddall SP, Carlin KM, Bell GD, Guise CP, Mowday AM, Hay MP, Smaill JB, Patterson AV, Ackerley DF.

Mol Cancer. 2013 Jun 10;12:58. doi: 10.1186/1476-4598-12-58.

23.

18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.

Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW.

J Nucl Med. 2013 Aug;54(8):1339-46. doi: 10.2967/jnumed.112.116293. Epub 2013 Jun 5.

24.

Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.

Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.

Biochem Pharmacol. 2012 Mar 1;83(5):574-85. doi: 10.1016/j.bcp.2011.12.005. Epub 2011 Dec 13.

PMID:
22182429
25.

The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.

Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR.

Clin Cancer Res. 2012 Mar 15;18(6):1684-95. doi: 10.1158/1078-0432.CCR-11-2296. Epub 2011 Dec 13.

26.

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.

Hunt MA, Li D, Hay MP, Currie MJ, Robinson BA, Patterson AV, Dachs GU.

J Gene Med. 2012 Jan;14(1):62-74. doi: 10.1002/jgm.1635.

PMID:
22147660
27.

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ.

Sci Transl Med. 2011 Aug 3;3(94):94ra70. doi: 10.1126/scitranslmed.3002394.

28.

Targeting hypoxia in cancer therapy.

Wilson WR, Hay MP.

Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064. Review.

PMID:
21606941
29.

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.

Bonnet M, Flanagan JU, Chan DA, Lai EW, Nguyen P, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2011 Jun 1;19(11):3347-56. doi: 10.1016/j.bmc.2011.04.042. Epub 2011 Apr 24.

30.

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.

Clin Cancer Res. 2010 Oct 15;16(20):4946-57. doi: 10.1158/1078-0432.CCR-10-1439. Epub 2010 Aug 20.

31.

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF.

J Am Chem Soc. 2010 Mar 3;132(8):2591-9. doi: 10.1021/ja908689f.

PMID:
20141134
32.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

33.

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF.

J Am Chem Soc. 2009 Oct 14;131(40):14220-1. doi: 10.1021/ja906860a.

PMID:
19772319
34.

One-electron reduction potential of the neutral guanyl radical in the GC base pair of duplex DNA.

Shinde SS, Maroz A, Hay MP, Anderson RF.

J Am Chem Soc. 2009 Apr 15;131(14):5203-7. doi: 10.1021/ja8087339.

35.

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, Denny WA.

J Med Chem. 2008 Nov 13;51(21):6853-65. doi: 10.1021/jm800967h. Epub 2008 Oct 11.

36.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

37.

Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.

Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, Shinde SS, Phillips V, Denny WA, Wilson WR.

J Med Chem. 2007 Dec 27;50(26):6654-64. Epub 2007 Dec 6.

PMID:
18052317
38.

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.

Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA.

J Med Chem. 2007 Dec 13;50(25):6392-404. Epub 2007 Nov 15.

PMID:
18001018
39.

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.

Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR.

J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28.

PMID:
16912264
40.
41.

Complete 1H, 13C and 15N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides.

Boyd M, Hay MP, Boyd PD.

Magn Reson Chem. 2006 Oct;44(10):948-54.

PMID:
16900565
42.

Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.

Anderson RF, Shinde SS, Hay MP, Denny WA.

J Am Chem Soc. 2006 Jan 11;128(1):245-9.

PMID:
16390153
43.

Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.

Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA.

Org Biomol Chem. 2005 Jun 7;3(11):2167-74. Epub 2005 Apr 29.

PMID:
15917906
44.

Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.

Hay MP, Wilson WR, Denny WA.

Bioorg Med Chem. 2005 Jun 2;13(12):4043-55. Epub 2005 Apr 25.

PMID:
15911317
45.

Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.

Pruijn FB, Sturman JR, Liyanage HD, Hicks KO, Hay MP, Wilson WR.

J Med Chem. 2005 Feb 24;48(4):1079-87.

PMID:
15715475
46.

Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.

Shinde SS, Anderson RF, Hay MP, Gamage SA, Denny WA.

J Am Chem Soc. 2004 Jun 30;126(25):7865-74.

PMID:
15212534
47.

Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.

Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.

Cancer Res. 2004 Jan 15;64(2):736-42.

48.

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.

Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA.

J Med Chem. 2004 Jan 15;47(2):475-88.

PMID:
14711317
49.

Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.

Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA.

J Med Chem. 2003 Dec 4;46(25):5533-45.

PMID:
14640560
50.

Supplemental Content

Support Center